CDC Website CDC Website

To Join the NPIN community or

Home » Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event -driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use. 

Application Due Date
5/6/19
Project Start Date
12/1/19
Application Contact
Ann
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
United States
240-669-2988
adevine@niaid.nih.gov
Technical Contact
Jim A.
Turpin, Ph.D.
Program Officer
jturpin@niaid.nih.gov
United States
301-451-2732
Fund Duration
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Subjects
Audiences
Focus Area

Fund Number: 

5461

Fund ID: 

PAR-19-209

Last Updated: 

3/8/19